PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to
see how well it works in treating patients with HIV-related Kaposi sarcoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) PTC Therapeutics The Emmes Company, LLC The EMMES Corporation